Several other analysts have also commented on APHA. CIBC lowered Aphria from a “neutral” rating to a “sector underperform” rating in a research note on Friday, July 26th. Zacks Investment Research raised Aphria from a “strong sell” rating to a “hold” rating in a research note on Friday, May 10th. Jefferies Financial Group started coverage on Aphria in a research note on Friday, May 24th. They issued a “buy” rating and a $11.00 target price for the company. Finally, Clarus Securities started coverage on Aphria in a research report on Tuesday, April 16th. They set a “buy” rating and a $22.75 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $14.75.
APHA traded down $0.18 during midday trading on Thursday, reaching $5.20. The company’s stock had a trading volume of 6,029,800 shares, compared to its average volume of 5,255,008. The stock has a market capitalization of $1.29 billion, a PE ratio of 37.14 and a beta of 3.12. The firm has a fifty day simple moving average of $6.48. Aphria has a twelve month low of $3.75 and a twelve month high of $16.86.
Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.
Read More: What is the return on assets formula?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.